Transitional First-Year Residents from Crozer Health Present Radiation Oncology Research
Two interns from the Crozer Health’s Transitional First-Year Residency Program presented studies at the American College of Radiation Oncology (ACRO) national meeting in Orlando, Florida on Mar. 9 to 11, 2017.
Anthony Ricco, M.D. presented “Lung Metastases Treated with Stereotatic Body Radiation Therapy (SBRT): The RSSearch® Patient Registry’s Experience.”
Anthony Ricco, M.D. presented “Lung Metastases Treated with Stereotactic Body Radiation Therapy (SBRT): The RSSearch® Patient Registry’s Experience.” The study followed 477 patients treated with SBRT for lung metastases enrolled nationally and internationally in the Radiosurgery Society patient registry. An overall five-year survival rate of 22 percent was noted for the entire group with better survival for cancers of the breast, head/neck and colon/rectum compared to lung. The study’s authors also found that the application of standard or higher dose SBRT to smaller tumors resulted in increased chances of survival.
The Radiosurgery Society’s patient registry database currently has about 20,000 patients enrolled, and this study was the sixth manuscript published describing outcomes of SRS/SBRT patients enrolled in RSSearch.
Mark Dziemianowicz, M.D. presented "Stereotactic Body Radiation Therapy for Treatment of Intermediate- and High-Risk Prostate Cancer."
Mark Dziemianowicz, M.D. studied men with intermediate- and high-risk prostate cancer treated at the Philadelphia CyberKnife center with SBRT. His study confirmed that the stratification system developed by Memorial Sloan Kettering for men treated for intermediate risk prostate cancer with Intensity Modulated Radiation Therapy (IMRT) is applicable to patients treated with SBRT as well. He also concluded that patients with favorable intermediate-risk did as well when treated with SBRT as patients with low-risk disease and may not benefit from androgen deprivation therapy while men with unfavorable intermediate risk did similar to those with high-risk disease and may benefit from androgen deprivation therapy. The results of SBRT compared favorably to clinical trials for similar risk men with prostate cancer treated with IMRT.
"We are very proud of the accomplishments of our transitional interns Anthony and Mark on their scholarly activities and so appreciative of the educational guidance of Dr. Lanciano and her colleagues and the financial support of their sponsorship,” said Dina Capalongo D.O., chief of Internal Medicine and program director of Crozer Health's Transitional Year Residency Program. "Anthony and Mark will graduate from the program in June and continue their training in radiation oncology residency programs."
Rachelle Lanciano, M.D., chair of Radiation Oncology at Delaware County Memorial Hospital, mentored both residents during their transition year. These residents will begin a four-year residency program in radiation oncology this July. “We really enjoy having transition year interns rotate through our radiation department and do clinical research with us,” said Lanciano. “These residents represent the future of radiation oncology, and we are so happy to contribute to their development in the field.”
About the Transitional First-Year Residency Program
Each year, a class of 14 residents enters the Crozer Health Transitional First Year Residency program. Located at Crozer-Chester Medical Center, the program’s broad-based curriculum provides residents with a valuable clinical experience and a strong foundation for their next level of training.
Crozer Health's Transitional First-Year Residency Program provides a well-rounded clinical and educational experience for new doctors embarking on their postdoctoral training. Based at the busy Crozer-Chester Medical Center, our program provides residents with a valuable introduction to clinical medicine in a variety of disciplines in both ambulatory and inpatient settings.
